Goldman Sachs analysts added Zai Lab (ZLAB) to the firm’s APAC Conviction List as part of its monthly update. The firm says the company is transitioning from a licensing-in based China-only model to an in-house plus licensing “dual engine” global opportunity-focused business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab Ltd’s Earnings Call Highlights Strong Growth
- Zai Lab Reports Strong Revenue Growth and Strategic Progress
- Zai Lab reports Q4 EPS (80c), consensus (63c)
- Zai Lab sees FY25 revenue $560M-$590M, consensus $567.84M
- Zai Lab’s Strategic Advancements and Global Potential in SCLC Treatment with ZL-1310